In the News

News & Publications

  • Filter by type

April 15, 2024 | Press Release
Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole

Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients […]

January 3, 2024 | Press Release
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering […]

October 16, 2023 | Press Release
Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole

LONDON – October 16, 2023 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients […]

June 8, 2023 | Press Release
Pulmocide Announces Expansion of Management Team

LONDON, June 08, 2023 — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering […]

December 6, 2022 | Press Release
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole

Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic […]

September 29, 2022 | Publications & Presentations
Novel inhaled antifungal for pseudomembranous Aspergillus tracheobronchitis complicating connective tissue disease

December 21, 2021 | Press Release
Pulmocide Receives Investment from the Cystic Fibrosis Foundation

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients […]

September 16, 2021 | Press Release
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients […]

May 27, 2021 | Press Release
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and […]

March 11, 2021 | Press Release
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections

London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, […]

Scroll to Top